PMID- 35752865
OWN - NLM
STAT- MEDLINE
DCOM- 20220628
LR  - 20221104
IS  - 1757-6512 (Electronic)
IS  - 1757-6512 (Linking)
VI  - 13
IP  - 1
DP  - 2022 Jun 25
TI  - Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in 
      ARDS: a systematic review and meta-analysis based on phase I and II RCTs.
PG  - 275
LID - 10.1186/s13287-022-02956-3 [doi]
LID - 275
AB  - BACKGROUND: Mesenchymal stromal cells (MSCs) therapy for acute respiratory 
      distress syndrome (ARDS) is an emerging treatment, but most of the current trials 
      of MSCs stay in the animal experimental stage, and the safety and efficacy of 
      MSCs in clinical application are not clear. We aimed to analyze the safety, 
      efficacy and biomarkers of mesenchymal stromal cells in the treatment of ARDS. 
      METHODS: For this systematic review and meta-analysis, we searched PubMed, 
      Embase, Cochrane Central Register of Controlled Trials, Web of science, CNKI, VIP 
      and Wan Fang data, studies published between database inception and Mar 17, 2022. 
      All randomized controlled trials (RCT) of stem cell interventions for ARDS were 
      included, without language or date restrictions. We did separate meta-analyses 
      for mortality, subjects with adverse events (AEs) and subjects with serious 
      adverse events (SAEs). Since the trials data are dichotomous outcomes, the odds 
      ratio (OR) is adopted for meta-analysis. The quality of the evidence was assessed 
      with the Cochrane risk of bias tool. FINDINGS: In total, 5 trials involving 171 
      patients with ARDS were included in this meta-analysis. A total of 99 individuals 
      were randomly assigned to receive MSCs treatment, and 72 were randomly assigned 
      to receive placebo treatment. Treatment with MSCs appeared to increase the 
      occurrence of adverse events, but this result was not statistically significant 
      (OR, 1.58; 95%CI, 0.64-3.91; P = 0.32). The occurrence of serious adverse events 
      was lower in the MSCs group than in the placebo group (OR, 0.57; 95%CI, 
      0.14-2.32; P = 0.43); there seems to be no significant difference between the two 
      groups in terms of 28 days mortality (OR, 0.93; 95%CI, 0.45-1.89); oxygenation 
      index and biomarkers showed a tendency to improve in treatment, but there was a 
      lack of more statistically significant clinical evidence to support them. 
      INTERPRETATION: Based on the current clinical trials, MSCs intervention has some 
      safety for ARDS patients, but its effectiveness and predictive value of airspace 
      biomarkers need to be determined by more large-scale, standard randomized 
      controlled trials.
CI  - (c) 2022. The Author(s).
FAU - Wang, Jianbao
AU  - Wang J
AD  - Department of Respiratory and Critical Care Medicine, Fujian Respiratory Medical 
      Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 
      City, Fujian Province, China.
FAU - Luo, Fenbin
AU  - Luo F
AD  - Department of Respiratory and Critical Care Medicine, Fujian Respiratory Medical 
      Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 
      City, Fujian Province, China.
FAU - Suo, Ye
AU  - Suo Y
AD  - Department of Respiratory and Critical Care Medicine, Fujian Respiratory Medical 
      Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 
      City, Fujian Province, China.
FAU - Zheng, Yuxin
AU  - Zheng Y
AD  - Department of Respiratory and Critical Care Medicine, Fujian Respiratory Medical 
      Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 
      City, Fujian Province, China.
FAU - Chen, Kaikai
AU  - Chen K
AD  - Department of Respiratory and Critical Care Medicine, Fujian Respiratory Medical 
      Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 
      City, Fujian Province, China.
FAU - You, Deyuan
AU  - You D
AD  - Department of Respiratory and Critical Care Medicine, Fujian Respiratory Medical 
      Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 
      City, Fujian Province, China.
FAU - Liu, Yuqi
AU  - Liu Y
AUID- ORCID: 0000-0003-0334-5349
AD  - Department of Respiratory and Critical Care Medicine, Fujian Respiratory Medical 
      Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 
      City, Fujian Province, China. fjydfseyicu@163.com.
LA  - eng
GR  - P30 CA086862/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20220625
PL  - England
TA  - Stem Cell Res Ther
JT  - Stem cell research & therapy
JID - 101527581
SB  - IM
MH  - Humans
MH  - *Mesenchymal Stem Cells
MH  - *Respiratory Distress Syndrome/therapy
PMC - PMC9233855
OTO - NOTNLM
OT  - Acute respiratory distress syndrome
OT  - Adverse events
OT  - Biomarkers
OT  - Mesenchymal stromal cells
OT  - Meta-analysis
OT  - Mortality
OT  - Serious adverse events
OT  - Stem cell
OT  - Systematic review
COIS- The authors have disclosed that they do not have any potential conflicts of 
      interest.
EDAT- 2022/06/26 06:00
MHDA- 2022/06/29 06:00
PMCR- 2022/06/25
CRDT- 2022/06/25 23:34
PHST- 2022/04/05 00:00 [received]
PHST- 2022/06/08 00:00 [accepted]
PHST- 2022/06/25 23:34 [entrez]
PHST- 2022/06/26 06:00 [pubmed]
PHST- 2022/06/29 06:00 [medline]
PHST- 2022/06/25 00:00 [pmc-release]
AID - 10.1186/s13287-022-02956-3 [pii]
AID - 2956 [pii]
AID - 10.1186/s13287-022-02956-3 [doi]
PST - epublish
SO  - Stem Cell Res Ther. 2022 Jun 25;13(1):275. doi: 10.1186/s13287-022-02956-3.